<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38260484</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Jan</Month><Day>12</Day></PubDate></JournalIssue><Title>medRxiv : the preprint server for health sciences</Title><ISOAbbreviation>medRxiv</ISOAbbreviation></Journal><ArticleTitle>Impact of COVID-19 vaccination on symptoms and immune phenotypes in vaccine-na&#xef;ve individuals with Long COVID.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2024.01.11.24300929</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/2024.01.11.24300929</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Long COVID contributes to the global burden of disease. Proposed root cause hypotheses include the persistence of SARS-CoV-2 viral reservoir, autoimmunity, and reactivation of latent herpesviruses. Patients have reported various changes in Long COVID symptoms after COVID-19 vaccinations, leaving uncertainty about whether vaccine-induced immune responses may alleviate or worsen disease pathology.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">In this prospective study, we evaluated changes in symptoms and immune responses after COVID-19 vaccination in 16 vaccine-na&#xef;ve individuals with Long COVID. Surveys were administered before vaccination and then at 2, 6, and 12 weeks after receiving the first vaccine dose of the primary series. Simultaneously, SARS-CoV-2-reactive TCR enrichment, SARS-CoV-2-specific antibody responses, antibody responses to other viral and self-antigens, and circulating cytokines were quantified before vaccination and at 6 and 12 weeks after vaccination.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Self-report at 12 weeks post-vaccination indicated 10 out of 16 participants had improved health, 3 had no change, 1 had worse health, and 2 reported marginal changes. Significant elevation in SARS-CoV-2-specific TCRs and Spike protein-specific IgG were observed 6 and 12 weeks after vaccination. No changes in reactivities were observed against herpes viruses and self-antigens. Within this dataset, higher baseline sIL-6R was associated with symptom improvement, and the two top features associated with non-improvement were high IFN-&#x3b2; and CNTF, among soluble analytes.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Our study showed that in this small sample, vaccination improved the health or resulted in no change to the health of most participants, though few experienced worsening. Vaccination was associated with increased SARS-CoV-2 Spike protein-specific IgG and T cell expansion in most individuals with Long COVID. Symptom improvement was observed in those with baseline elevated sIL-6R, while elevated interferon and neuropeptide levels were associated with a lack of improvement.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Grady</LastName><ForeName>Connor B</ForeName><Initials>CB</Initials><Identifier Source="ORCID">0000-0001-8407-846X</Identifier><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhattacharjee</LastName><ForeName>Bornali</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbial Pathogenesis, Yale University School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Julio</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jaycox</LastName><ForeName>Jillian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Lik Wee</ForeName><Initials>LW</Initials><AffiliationInfo><Affiliation>Adaptive Biotechnologies, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monteiro</LastName><ForeName>Valter Silva</ForeName><Initials>VS</Initials><AffiliationInfo><Affiliation>Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sawano</LastName><ForeName>Mitsuaki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Massey</LastName><ForeName>Daisy</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caraballo</LastName><ForeName>C&#xe9;sar</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gehlhausen</LastName><ForeName>Jeff R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tabachnikova</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Tianyang</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lucas</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pe&#xf1;a-Hernandez</LastName><ForeName>Mario A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbial Pathogenesis, Yale University School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Lan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tzeng</LastName><ForeName>Tiffany J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Takehiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrin</LastName><ForeName>Jeph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xfc;the</LastName><ForeName>Diana Berrent</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>Survivor Corps.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akrami</LastName><ForeName>Athena</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sainsbury Wellcome Centre, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Patient-Led Research Collaborative.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Assaf</LastName><ForeName>Gina</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Patient-Led Research Collaborative.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Hannah</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Patient-Led Research Collaborative.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Survivor Corps.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCorkell</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Patient-Led Research Collaborative.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schulz</LastName><ForeName>Wade L</ForeName><Initials>WL</Initials><AffiliationInfo><Affiliation>Center for Infection and Immunity, Yale School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Yale University School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grffin</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York City, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Hannah</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Patient-Led Research Collaborative.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ring</LastName><ForeName>Aaron M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guan</LastName><ForeName>Leying</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center for Infection and Immunity, Yale School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruz</LastName><ForeName>Charles Dela</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Department of Microbial Pathogenesis, Yale University School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Infection and Immunity, Yale School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Section of Pulmonary and Critical Care Medicine, Yale University School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwasaki</LastName><ForeName>Akiko</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Infection and Immunity, Yale School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Chevy Chase, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krumholz</LastName><ForeName>Harlan M</ForeName><Initials>HM</Initials><Identifier Source="ORCID">0000-0003-2046-127X</Identifier><AffiliationInfo><Affiliation>Center for Infection and Immunity, Yale School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI157488</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 FD005938</GrantID><Acronym>FD</Acronym><Agency>FDA HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>medRxiv</MedlineTA><NlmUniqueID>101767986</NlmUniqueID></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>23</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>23</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>23</Day><Hour>10</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38260484</ArticleId><ArticleId IdType="pmc">PMC10802754</ArticleId><ArticleId IdType="doi">10.1101/2024.01.11.24300929</ArticleId><ArticleId IdType="pii">2024.01.11.24300929</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Iacobucci G. Long covid: Damage to multiple organs presents in young, low risk patients. BMJ m4470 (2020) doi:10.1136/bmj.m4470.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m4470</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y. et al. COVID Symptoms, Symptom Clusters, and Predictors for Becoming a Long-Hauler Looking for Clarity in the Haze of the Pandemic. Clin. Nurs. Res. 31, 1390&#x2013;1398 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9510954</ArticleId><ArticleId IdType="pubmed">36154716</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehme M. et al. COVID-19 Symptoms: Longitudinal Evolution and Persistence in Outpatient Settings. Ann. Intern. Med. 174, 723&#x2013;725 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7741180</ArticleId><ArticleId IdType="pubmed">33284676</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahoney L. L. et al. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. eClinicalMedicine 55, (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9714474</ArticleId><ArticleId IdType="pubmed">36474804</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T., Knight M., A&#x2019;Court C., Buxton M. &amp; Husain L. Management of post-acute covid-19 in primary care. BMJ 370, m3026 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre C. H. et al. Attributes and predictors of long COVID. Nat. Med. 27, 626&#x2013;631 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H. E. et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 38, 101019 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert N. et al. The other COVID-19 survivors: Timing, duration, and health impact of post-acute sequelae of SARS-CoV-2 infection. J. Clin. Nurs. n/a,.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9538514</ArticleId><ArticleId IdType="pubmed">36181315</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.
An Exploratory, Randomized, Double-Blind Placebo-Controlled Study to Assess the Safety of an Anti-SARS-CoV-2 Monoclonal Antibody and Response to Treatment in Individuals With Long COVID (outSMART-LC). https://clinicaltrials.gov/study/NCT05877508 (2023).</Citation></Reference><Reference><Citation>Krumholz H. M.
An Interventional Decentralized Phase 2, Randomized, Double-Blind, 2-Arm Study to Investigate the Efficacy and Safety of Orally Administered Nirmatrelvir/Ritonavir Compared With Placebo/Ritonavir in Participants With Long COVID. https://clinicaltrials.gov/study/NCT05668091 (2023).</Citation></Reference><Reference><Citation>Stanford University. Selective Trial Of Paxlovid for PASC (STOP-PASC): Randomized Double-Blind Placebo-Controlled Pilot Trial of Paxlovid for the Treatment of PASC. https://clinicaltrials.gov/study/NCT05576662 (2023).</Citation></Reference><Reference><Citation>Yonker L.
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Larazotide (AT1001) for the Treatment of Long COVID in Children and Young Adults. https://clinicaltrials.gov/study/NCT05747534 (2023).</Citation></Reference><Reference><Citation>Proal A. D. et al. SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC). Nat. Immunol. 24, 1616&#x2013;1627 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37667052</ArticleId></ArticleIdList></Reference><Reference><Citation>Choutka J., Jansari V., Hornig M. &amp; Iwasaki A. Unexplained post-acute infection syndromes. Nat. Med. 28, 911&#x2013;923 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35585196</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H. E., McCorkell L., Vogel J. M. &amp; Topol E. J. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 21, 133&#x2013;146 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan A. et al. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med N. Y. N 3, 371&#x2013;387.e9 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9005383</ArticleId><ArticleId IdType="pubmed">35434682</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank Z. et al. Persistent Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Spike Is Associated With Post-acute Coronavirus Disease 2019 Sequelae. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 76, e487&#x2013;e490 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte K. I. et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review. EClinicalMedicine 53, 101624 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9417563</ArticleId><ArticleId IdType="pubmed">36051247</ArticleId></ArticleIdList></Reference><Reference><Citation>Nayyerabadi M. et al. Vaccination after developing long COVID: impact on clinical presentation, viral persistence and immune responses. Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis. S1201&#x2013;9712(23)00720&#x2013;8 (2023) doi:10.1016/j.ijid.2023.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2023.09.006</ArticleId><ArticleId IdType="pubmed">37717649</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki A. &amp; Putrino D. Why we need a deeper understanding of the pathophysiology of long COVID. Lancet Infect. Dis. 23, 393&#x2013;395 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9928485</ArticleId><ArticleId IdType="pubmed">36967698</ArticleId></ArticleIdList></Reference><Reference><Citation>Duradoni M., Gursesli M. C., Materassi L., Serritella E. &amp; Guazzini A. The Long-COVID Experience Changed People&#x2019;s Vaccine Hesitancy but Not Their Vaccination Fear. Int. J. Environ. Res. Public. Health 19, 14550 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9654193</ArticleId><ArticleId IdType="pubmed">36361430</ArticleId></ArticleIdList></Reference><Reference><Citation>Massey D. et al. Change in Symptoms and Immune Response in People with Post-Acute Sequelae of SARS-Cov-2 Infection (PASC) After SARS-Cov-2 Vaccination. 2021.07.21.21260391 Preprint at 10.1101/2021.07.21.21260391 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.21.21260391</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki A.
How Vaccines Might Improve Long Covid. Elemental
https://elemental.medium.com/how-vaccines-might-improve-long-covid-c1f41c4d7378 (2021).</Citation></Reference><Reference><Citation>Prof. Akiko Iwasaki [@VirusesImmunity]. This video shows that vaccines have helped some people with #longCOVID with their symptoms. While the numbers are still small in some groups, there are encouraging signs (also via @DanielGriffinMD). I present my hypothesis on how vaccines might improve #LongCovid (1/). Twitter
https://twitter.com/VirusesImmunity/status/1366067849480048643 (2021).</Citation></Reference><Reference><Citation>Vaccine Survey &#x2013; Patient Led Research Collaborative. https://patientresearchcovid19.com/vaccine-survey/.</Citation></Reference><Reference><Citation>Johns Hopkins COVID Long Study. Johns Hopkins COVID Long Study
https://covid-long.com/.</Citation></Reference><Reference><Citation>Lambert N. J., Corps S., El-Azab S., Yu L. &amp; Esperanca A. Fever Scans Offer False Sense of Security for Stopping the Spread of COVID-19. (2020).</Citation></Reference><Reference><Citation>Lambert N. J. &amp; Corps S. COVID-19 &#x201c;Long Hauler&#x201d; Symptoms Survey Report. (2020).</Citation></Reference><Reference><Citation>Assaf G.
et al.
Report: What Does COVID-19 Recovery Actually Look Like? &#x2013; Patient Led Research Collaborative. https://patientresearchcovid19.com/research/report-1/.</Citation></Reference><Reference><Citation>Klein J. et al. Distinguishing features of Long COVID identified through immune profiling. MedRxiv Prepr. Serv. Health Sci. 2022.08.09.22278592 (2022) doi:10.1101/2022.08.09.22278592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.08.09.22278592</ArticleId><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder T. M. et al. Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels. MedRxiv Prepr. Serv. Health Sci. 2020.07.31.20165647 (2020) doi:10.1101/2020.07.31.20165647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.07.31.20165647</ArticleId></ArticleIdList></Reference><Reference><Citation>Adaptive Biotechnologies Corporation. Emergency Use Authorization (EUA) Summmary T-Detect COVID Test. (2021).</Citation></Reference><Reference><Citation>Klinger M. et al. Multiplex Identification of Antigen-Specific T Cell Receptors Using a Combination of Immune Assays and Immune Receptor Sequencing. PloS One 10, e0141561 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4624875</ArticleId><ArticleId IdType="pubmed">26509579</ArticleId></ArticleIdList></Reference><Reference><Citation>Leek J. T., Johnson W. E., Parker H. S., Jaffe A. E. &amp; Storey J. D. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28, 882&#x2013;883 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3307112</ArticleId><ArticleId IdType="pubmed">22257669</ArticleId></ArticleIdList></Reference><Reference><Citation>R Core Team. R: A language and environment for statistical computing.</Citation></Reference><Reference><Citation>Morpheus. https://software.broadinstitute.org/morpheus/.</Citation></Reference><Reference><Citation>Wold S., Johansson E. &amp; Cocchi M. PLS: Partial Least Squares Projections to Latent Structures. in (1993).</Citation></Reference><Reference><Citation>Kubinyi H. 3D QSAR in drug design : theory, methods and applications. in (2000).</Citation></Reference><Reference><Citation>Su Y. et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell 185, 881&#x2013;895.e20 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold J. E., Okyay R. A., Licht W. E. &amp; Hurley D. J. Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation. Pathog. Basel Switz. 10, 763 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang E. Y. et al. Diverse functional autoantibodies in patients with COVID-19. Nature 595, 283&#x2013;288 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaycox J. R. et al. SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity. Nat. Commun. 14, 1299 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9996559</ArticleId><ArticleId IdType="pubmed">36894554</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuchida T. et al. Relationship between changes in symptoms and antibody titers after a single vaccination in patients with Long COVID. J. Med. Virol. 94, 3416&#x2013;3420 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9088489</ArticleId><ArticleId IdType="pubmed">35238053</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe A., Iwagami M., Yasuhara J., Takagi H. &amp; Kuno T. Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis. Vaccine 41, 1783&#x2013;1790 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9905096</ArticleId><ArticleId IdType="pubmed">36774332</ArticleId></ArticleIdList></Reference><Reference><Citation>Byambasuren O., Stehlik P., Clark J., Alcorn K. &amp; Glasziou P. Effect of covid-19 vaccination on long covid: systematic review. BMJ Med. 2, e000385 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9978692</ArticleId><ArticleId IdType="pubmed">36936268</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold D. T. et al. Are vaccines safe in patients with Long COVID? A prospective observational study. 2021.03.11.21253225 Preprint at 10.1101/2021.03.11.21253225 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.11.21253225</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehme M. et al. Symptoms After COVID-19 Vaccination in Patients with Post-Acute Sequelae of SARS-CoV-2. J. Gen. Intern. Med. 37, 1585&#x2013;1588 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8863092</ArticleId><ArticleId IdType="pubmed">35194744</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran V.-T., Perrodeau E., Saldanha J., Pane I. &amp; Ravaud P. Efficacy of first dose of covid-19 vaccine versus no vaccination on symptoms of patients with long covid: target trial emulation based on ComPaRe e-cohort. BMJ Med. 2, e000229 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9978748</ArticleId><ArticleId IdType="pubmed">36910458</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmerman K. O.
RECOVER-VITAL: A Platform Protocol for Evaluation of Interventions for Viral Persistence, Viral Reactivation, and Immune Dysregulation in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC). https://clinicaltrials.gov/study/NCT05595369 (2023).</Citation></Reference><Reference><Citation>Brodin P.
An Interventional, Double-Blinded, 2-Arm Study to Investigate the Efficacy of Orally Administered Nirmatrelvir/Ritonavir Compared With Placebo/Ritonavir in Non-hospitalized Adult Participants Suffering From Post-COVID. https://clinicaltrials.gov/study/NCT05823896 (2023).</Citation></Reference><Reference><Citation>Wong A. C. et al. Serotonin reduction in post-acute sequelae of viral infection. Cell 186, 4851&#x2013;4867.e20 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11227373</ArticleId><ArticleId IdType="pubmed">37848036</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>